Koers Xenetic Biosciences Inc Other OTC
Aandelen
US9840151073
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 1,76 mln. 2,23 mln. 2,05 mln. | Omzet 2025 * | 1,44 mln. 1,82 mln. 1,68 mln. | Marktkapitalisatie | 4,81 mln. 6,1 mln. 5,61 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -5,07 mln. -4,66 mln. | Nettowinst (verlies) 2025 * | -7 mln. -8,87 mln. -8,16 mln. | EV/omzet 2024 * | 2,74 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 3,35 x |
K/w-verhouding 2024 * |
-4,12
x | K/w-verhouding 2025 * |
-5,42
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 80,81% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 03-04-17 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-03-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 58 | 11-07-16 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 14-08-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,52% | 113 mld. | |
+11,38% | 106 mld. | |
-12,64% | 22,22 mld. | |
+0,44% | 22,27 mld. | |
-4,18% | 19,43 mld. | |
-37,85% | 17,87 mld. | |
-8,58% | 17,24 mld. | |
+37,41% | 12,52 mld. | |
-23,95% | 8,34 mld. |
- Beurs
- Aandelen
- Koers XBIO
- Koers